Company / R&D per Share
10x Genomics, Inc. R&D per Share History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.95
FY2025
5-year range
$1.95 / $2.36
FY2021-FY2025
Trend
-12.2%
vs FY2024
Sector context
#47 of 103
Health Care
What the data says
At $1.95, 10x Genomics, Inc.'s r&d per share ranks #47 of 103 in the Health Care sector. R&D per Share has declined for 3 consecutive years, from $2.36 in FY2022 to $1.95 in FY2025.
Based on SEC 10-K filings.
1.95 in FY2025 with a 5-year CAGR of +8.8%.
Declined from $2.35 to $1.95 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -6.2%
- 5-Year CAGR
- +8.8%
- 10-Year CAGR
- -
Sector benchmark
#47 of 103 in Health CareTop 46% of 103This company $1.95 Sector average $2.13
▼
-8.5% below sector average
Key checks
Key Insights
- 10x Genomics, Inc.'s r&d per share has declined for 3 consecutive years.
- In FY2025, r&d per share decreased 12.2% year-over-year.
- Ranks #47 out of 103 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -29.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.95 | -12.2% |
| FY2024 | $2.22 | -5.3% |
| FY2023 | $2.35 | -0.6% |
| FY2022 | $2.36 | +21.0% |
| FY2021 | $1.95 | +52.3% |
| FY2020 | $1.28 | -77.6% |
| FY2019 | $5.71 | +60.9% |
| FY2018 | $3.55 | +27.9% |
| FY2017 | $2.78 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026